To include your compound in the COVID-19 Resource Center, submit it here.

Pathway: Function follows PI3K isoform

Pathway's cancer compound selectively inhibits the PI3K alpha isoform and mTOR

Many PI3K inhibitors in development cause severe side effects that limit dosing, and most mTOR inhibitors have limited effectiveness because they target only one of the two mTOR complexes involved in cancer call growth. Pathway Therapeutics Inc. thinks its dual PI3K alpha/mTOR inhibitor can treat solid tumors more effectively and safely because it selectively targets a single PI3K isoform and both mTOR complexes.

Signaling by phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR; FRAP; RAFT1) promotes a diverse range of cellular functions, including cell growth, proliferation, survival and

Read the full 884 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE